The verdict
Our read at a glance.
Whether exact leuprolide and leuprolide-acetate evidence supports approved product-specific GnRH agonist contexts, and how to separate that evidence from native GnRH, other GnRH-pathway drugs, compounded products, research-use products, internet-market products, and broad endocrine-optimization claims.
- The signal
- This memo draws on 83 vetted references, 65 of them curated into the public source list. FDA, DailyMed, ClinicalTrials.gov, NCI/NCATS, and major-regulator records establish identity, product status, label context, and non-equivalence boundaries. PubMed human studies support prostate-cancer androgen-deprivation contexts, central precocious puberty, endometriosis, uterine fibroids, selected breast-cancer ovarian-suppression contexts, and comparator/safety interpretation. Reviews and mechanism sources support GnRH agonist receptor biology without turning class pharmacology into broad wellness evidence.
- The unknown
- How future labels, safety communications, and comparative trials will change product-specific benefit-risk interpretation, and how reliably public sources can keep leuprolide acetate, leuprolide mesylate, leuprorelin products, historical products, non-U.S. records, compounded products, research-use products, and internet-market claims separate.
- Our read
- Source-rich, but not broadly generalizable. Leuprolide is an approved GnRH agonist drug in specific product contexts; the Watchlist issue is keeping those evidence-backed uses separate from online peptide, wellness, fertility-optimization, and generic hormone-pathway claims.
The mechanism
How it works.
Leuprolide is a long-acting GnRH agonist, a synthetic peptide that copies the hypothalamic GnRH signal but resists breakdown so it lingers. It binds pituitary GnRH receptors and at first stimulates a surge of LH and FSH, but because the exposure is continuous rather than pulsatile, the receptors quickly desensitize and downregulate. The result is a sustained drop in LH, FSH, and the sex steroids they drive, which is the basis for its approved uses in prostate cancer, central precocious puberty, and endometriosis.
Safety & regulatory boundary
The consequential part.
Current label and regulator sources support a safety-watch frame. The boundary is product-specific: labels differ by salt, product system, population, and approved context. Safety sources include label warnings, regulator safety communications, cardiovascular and metabolic ADT context, pseudotumor cerebri labeling context, severe cutaneous adverse reaction labeling context, hypersensitivity reports, and bone-health guidance. Case reports and pharmacovigilance signals cannot estimate incidence.
What's next
What we're watching.
Watch DailyMed and openFDA label/status updates, FDA review or safety communications, ClinicalTrials.gov records, PubMed comparative safety evidence, major-regulator records, and any source maps that clarify acetate versus mesylate, leuprorelin terminology, product-specific labels, and comparator GnRH-pathway drugs.
Context
Why this is discussed.
Leuprolide sits in the same reproductive-axis pathway as GnRH/gonadorelin, but it is a long-acting agonist drug with extensive label and trial history. That makes it easy for public discussion to blur approved product evidence with broader hormone, fertility, wellness, bodybuilding, or peptide-market claims that the sources do not support.
The evidence base
65 cited references.
Regulatory & labels24
Food and Drug Administration / GSRS · Checked 2026-05-19
Food and Drug Administration / GSRS · Checked 2026-05-19
National Library of Medicine / FDA label · Updated 2026-04-30; listing checked 2026-05-19
National Library of Medicine / FDA label · Updated 2025-09-25; listing checked 2026-05-19
National Library of Medicine / FDA label · Updated 2025-09-18; listing checked 2026-05-19
National Library of Medicine / FDA label · Updated 2025; listing checked 2026-05-19
National Library of Medicine / FDA label · Updated 2025-11-26; listing checked 2026-05-19
National Library of Medicine / FDA label · Published 2026-01-28; listing checked 2026-05-19
National Library of Medicine / FDA label · Published 2026-02-19; listing checked 2026-05-19
Food and Drug Administration / openFDA · API last updated 2026-05-15; checked 2026-05-19
Food and Drug Administration / Drugs@FDA · 1998 approval package; page created 2001
Food and Drug Administration / CDER · 2020
Food and Drug Administration / CDER · 2020
Food and Drug Administration / CDER · 2023
Food and Drug Administration / OOPD · Designation 1988; checked 2026-05-19
Health Canada Drug Product Database · Monograph date 2025-11-13; checked 2026-05-19
Health Canada · 1999 notice; checked 2026-05-19
European Medicines Agency · Authorization 2022; product info updated 2026-05-11
European Medicines Agency · 2020
Food and Drug Administration · 2022-07-01
Food and Drug Administration / CDER · 2025-09-23
Food and Drug Administration · 2010 archive
AHA / ACS / AUA advisory · 2010
ASCO / Cancer Care Ontario · 2020
Registered trials2
ClinicalTrials.gov / AbbVie · Completed; last update 2024-05-29
ClinicalTrials.gov / Abbott · Completed; last update 2011-07-19
Indexed literature (PubMed)33
Garnick MB · 1986
Komura E et al. · 2014
Shore ND et al. · 2019
Freedland SJ et al. · 2023
Shore ND et al. · 2026
Taplin ME et al. · 2014
Rozet F et al. · 2026
Shore ND et al. · 2020
Lopes RD et al. · 2021
Guzick DS et al. · 2011
Strowitzki T et al. · 2010
Strowitzki T et al. · 2012
Dawood MY et al. · 1995
Crosignani PG et al. · 2006
Friedman AJ et al. · 1988
Palomba S et al. · 2002
Stovall TG et al. · 1995
Fuld K et al. · 2011
Lee PA et al. · 2011
Neely EK et al. · 2010
Kim YJ et al. · 2013
Klein KO et al. · 2023
Klein KO et al. · 2026
Noguchi S et al. · 2016
Miller DS et al. · 1992
Plosker GL, Brogden RN · 1994
Chrisp P, Sorkin EM · 1991
Wilson AC et al. · 2007
Casati L et al. · 2023
Millar RP et al. · 2004
Omar AA et al. · 2020
Garrahy A et al. · 2021
Pediatric center study · 2022
Sponsor & other sources6
National Cancer Institute · Checked 2026-05-19
National Cancer Institute · Checked 2026-05-19
NCATS Inxight Drugs · Page edited 2025-04-02; checked 2026-05-19
IUPHAR/BPS Guide to Pharmacology · Checked 2026-05-19
LiverTox / NCBI Bookshelf · Updated 2023
Endotext / NCBI Bookshelf · Current online chapter checked 2026-05-19
Keep reading